Tranzyme Pharma initiates dosing in Phase II gastroparesis trial
This Phase II, randomized, double-blind, placebo-controlled study to be conducted at multiple sites in the US and Europe, will evaluate the safety and efficacy of three 28-day, once-daily,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.